Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Shoichiro Ohtani"'
Autor:
Toshimi Takano, Nobuaki Sato, Takashi Morimoto, Masakazu Toi, Satoshi Morita, Kenji Higaki, Shoichiro Ohtani, Makiko Mizutani, Tomomi Fujisawa, Nobuki Matsunami, Yasuhiro Yanagita, Norikazu Masuda, Shinji Ohno, Yutaka Yamamoto, Sachiko Tanaka-Mizuno, Koji Kaneko, Takayuki Kadoya, Masato Takahashi, Hiroshi Ishiguro
Publikováno v:
Breast Cancer Research and Treatment
Purpose Our primary objective was to determine the benefit/risk of anthracycline-free regimens by comparing docetaxel + cyclophosphamide (TC) alone, fluorouracil + epirubicin + cyclophosphamide (FEC) followed by TC, or TC followed by FEC as a primary
Autor:
Yasuhiko Sakata, Yukiko Kajiwara, Yuri Takamatsu, Ayako Ueno, Takanori Kin, Mitsuya Ito, Miwa Fujihara, Reina Maeda, Shoichiro Ohtani, Kensuke Kawasaki, Koichi Hiraki, Keisuke Abe
Publikováno v:
World Journal of Oncology
Background: The aim of this phase II study was to evaluate combined nab-paclitaxel (nab-PTX) with sequential anthracycline-based therapy as a neoadjuvant chemotherapy. Methods: We enrolled 41 patients with advanced breast cancer (stage IIA - IIIC). A
Autor:
Norikazu Masuda, Nobuaki Sato, Shoichiro Ohtani, Nobuki Matsunami, Masahiro Kashiwaba, Jun Yamamura, Takayuki Ueno, Satoshi Morita, Masato Takahashi, Shinji Ohno, Toshimi Takano, Masakazu Toi, Koji Kaneko
Publikováno v:
Japanese Journal of Clinical Oncology
Background The original aim of this study was to evaluate the treatment sequence and anthracycline requirement in docetaxel, cyclophosphamide and trastuzumab therapy. After one death in the anthracycline-containing arm, the protocol was amended to te
Autor:
Tomoyuki Aruga, Nobuyasu Suganuma, Norikazu Masuda, Hiroji Iwata, Shinji Ohno, Hironori Haga, Eriko Tokunaga, Satoshi Morita, Shoichiro Ohtani, Hideo Shigematsu, Toshimi Takano, Kenichi Inoue, Tomomi Fujisawa, Katsumasa Kuroi, Naohito Yamamoto, Kenjiro Aogi, Masahiro Takada, Masakazu Toi, Kenichi Sakurai, Hiroko Bando
Publikováno v:
Cancers
Cancers, Vol 13, Iss 4008, p 4008 (2021)
Volume 13
Issue 16
Cancers, Vol 13, Iss 4008, p 4008 (2021)
Volume 13
Issue 16
We conducted the Neo-LaTH study in which patients were randomized to different lengths of neoadjuvant induction anti-HER2 therapy with lapatinib and trastuzumab followed by weekly paclitaxel plus the anti-HER2 therapy, and in estrogen receptor (ER)-p
Autor:
Takafumi Sangai, Mitsuhiro Hayashi, Masayuki Nagahashi, Takashi Chishima, Tomohiko Ohta, Masaru Miyashita, Kohei Akazawa, Norio Kohno, Akira Yamada, T Iwatani, Takeshi Ishikawa, Masato Suzuki, Manabu Futamura, Hiroshi Kaise, Yoshinori Hasegawa, Shoichiro Ohtani, T Kubota, Yasuo Miyoshi, Hirokazu Tanino, Yoshimasa Kosaka
Publikováno v:
Cancer Research. 79:OT1-05
Background: It is well known that the prognosis of non pCR TNBC patients was poor after anthracycline and taxan treatment. For such patients, capecitabine seems to be effective to reduce recurrence based on the HR 0.58 of the CREATE X trial (Masuda,
Autor:
Nobuaki Sato, Tomoyuki Aruga, Kenjiro Aogi, Shintaro Takao, Satoshi Morita, Shigeto Maeda, Shoichiro Ohtani, Masahiro Kitada, Takashi Morimoto, Norikazu Masuda, Tomomi Fujisawa, Kenichi Watanabe, Takafumi Sangai, Shinji Ohno, Masakazu Toi, Hidetoshi Kawagichi
Publikováno v:
International Journal of Clinical Oncology
Background Anthracycline (A) or taxane T-based regimens are the standard early-line chemotherapy for metastatic breast cancer (BC). A previous study has shown a survival benefit of eribulin in heavily pretreated advanced/recurrent BC patients. The pr
Autor:
Shoichiro Ohtani, Nobuki Matsunami, Yuko Tanabe, Toshimi Takano, Takashi Morimoto, Tsutomu Takashima, Yoshifumi Komoike, Jun Yamamura, Ryoji Kato, Junji Tsurutani, Yutaka Mizuno, Satomi Watanabe, Yasuyuki Kojima, Tsutomu Iwasa, Tetsuhiro Yoshinami, Kazuhiko Nakagawa
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
BMC Cancer
BMC Cancer
Background We previously reported the synergistic effect of S-1 and eribulin in preclinical models. In addition, our phase I study revealed the recommended dose for the phase II study of the combination therapy in advanced breast cancer (ABC) patient
Autor:
Norikazu Masuda, Hiroyuki Yasojima, Hiroji Iwata, Masaya Hattori, Satoshi Morita, Shinji Ohno, Akiyo Yoshimura, Hiroshi Ishiguro, Shoichiro Ohtani
Publikováno v:
Breast Cancer (Tokyo, Japan)
Eribulin is a nontaxane microtubule inhibitor with activity in patients with metastatic breast cancer (MBC). We conducted a phase I dose-finding study of eribulin and capecitabine in patients with MBC pretreated with anthracycline and taxane.Women wi
Autor:
Seock-Ah Im, Yasuhiro Yanagita, Shintaro Takao, Isao Yokota, Soo Jung Lee, K. H. Park, Ae-Ree Kim, Sung-Bae Kim, Shoichiro Ohtani, Hironobu Sasano, Eun Sook Lee, Norikazu Masuda, Katsumasa Kuroi, Shinji Ohno, Hiroji Iwata, Masakazu Toi, Joon Jeong, Young-Hyuck Im, Byeong Woo Park, Yasuo Ohashi, Kenjiro Aogi
Publikováno v:
New England Journal of Medicine. 376:2147-2159
BackgroundPatients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)–negative breast cancer have poor prognoses. The benefit of adjuvant chemotherapy in these pati
Autor:
Shoichiro Ohtani, Takaaki Ao, Keiki Kawakami, Tomokazu Yamakawa, Satoshi Tamaru, Kenichi Watanabe, Takuya Iwamoto, Kazuya Ooi, Shinichi Kageyama, Tomomi Yamada, Makoto Simomura, Yasuhiko Sakata, Toshiro Mizuno, Susumu Ban, Akiya Mori, Satoshi Yokoyama, Naomi Konishi, Daisuke Nakanishi, Shinya Tamaki
Publikováno v:
Clinical breast cancer. 18(2)
Introduction Breast cancer patients often receive anthracycline-based chemotherapy, and chemotherapy-induced nausea and vomiting (CINV) remains one of the most uncomfortable and distressing adverse reactions. Poor control of CINV reduces the relative